Charles River Laboratories shares are trading higher after the company reported Q4 EPS of $1.49, beating the $1.40 estimate and Q4 sales of $601.5 million, beating the $590.75 million estimate; the company reported it sees FY19 sales growth of 10%-15%.
Benzinga Newsdesk